Skip to content
Open access · CC-BY via OpenAlex

Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease

Giorgio Turconi, Farhan Alam, Tanima SenGupta, Sini Pirnes-Karhu, Soophie Olfat, Mark S. Schmidt, Kärt Mätlik, Ana Montaño-Rodriguez, Vladimir Heiskanen, Daniel R. Garton, Petteri T. Piepponen, Charles Brenner, Carina I. Holmberg, Hilde Loge Nilsen, Eija Pirinen

Heliyon · 2024 · ▲ 7 citations

Abstract

Parkinson's disease (PD) is associated with a reduction in 26/20S proteasome and mitochondrial function and depletion of dopamine. Activation of mitochondrial function with the NAD + precursor nicotinamide riboside (NR) is a potential therapeutic for PD. However, despite recently started clinical trials, analysis of NR in mammalian animal PD models is lacking and data in simpler PD models is limited. We analyzed the effect of NR in C. elegans and in mouse 26/20S proteasome inhibition models of PD. In C. elegans , NR rescued α-synuclein overexpression induced phenotypes likely by activating the mitochondrial unfolded protein response. However, in a proteasome inhibitor-induced mouse model of PD, NR first partially rescued behavioural dysfunction, but later resulted in decrease in dopamine and its related gene expression in the substantia nigra. Our results suggest that reduction in 26/20S function with long term NR treatment may increase risk for developing reduced nigrostriatal DA function.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.heliyon.2024.e34355
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Turconi, G., Alam, F., SenGupta, T., Pirnes-Karhu, S., Olfat, S., Schmidt, M.S., Mätlik, K., Montaño-Rodriguez, A., Heiskanen, V., Garton, D.R., Piepponen, P.T., Brenner, C., Holmberg, C.I., Nilsen, H.L., Pirinen, E., &amp; Andressoo, J. (2024). Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease. <em>Heliyon</em>. https://doi.org/10.1016/j.heliyon.2024.e34355
Vancouver
Turconi G, Alam F, SenGupta T, Pirnes-Karhu S, Olfat S, Schmidt MS, et al. Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease. Heliyon. 2024. doi:10.1016/j.heliyon.2024.e34355.
BibTeX
@article{giorgio2024Nicoti, title = {Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease}, author = {Giorgio Turconi and Farhan Alam and Tanima SenGupta and Sini Pirnes-Karhu and Soophie Olfat and Mark S. Schmidt and Kärt Mätlik and Ana Montaño-Rodriguez and Vladimir Heiskanen and Daniel R. Garton and Petteri T. Piepponen and Charles Brenner and Carina I. Holmberg and Hilde Loge Nilsen and Eija Pirinen and Jaan‐Olle Andressoo}, journal = {Heliyon}, year = {2024}, doi = {10.1016/j.heliyon.2024.e34355}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings